Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Lymphocytic Leukemia
‘Modular’ Leukemia Drug Shows Promise in Early Testing
July 22nd, 2007
A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows. The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells. The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells’ self-destruction and by causing a particular class of immune cells to attack them. In an animal model, the agent worked equally as well as...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
